DE69928236T2 - Peptid für die diagnose von schizophrenie - Google Patents
Peptid für die diagnose von schizophrenie Download PDFInfo
- Publication number
- DE69928236T2 DE69928236T2 DE69928236T DE69928236T DE69928236T2 DE 69928236 T2 DE69928236 T2 DE 69928236T2 DE 69928236 T DE69928236 T DE 69928236T DE 69928236 T DE69928236 T DE 69928236T DE 69928236 T2 DE69928236 T2 DE 69928236T2
- Authority
- DE
- Germany
- Prior art keywords
- seq
- peptide
- schizophrenia
- peptides
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 87
- 201000000980 schizophrenia Diseases 0.000 title claims description 38
- 238000003745 diagnosis Methods 0.000 title claims description 10
- 230000027455 binding Effects 0.000 claims description 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 37
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000000523 sample Substances 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 230000000698 schizophrenic effect Effects 0.000 description 23
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 20
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 20
- 229940127236 atypical antipsychotics Drugs 0.000 description 19
- 210000001772 blood platelet Anatomy 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N Histidine Chemical group OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000004623 platelet-rich plasma Anatomy 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 101710113670 Anaerobic glycerol-3-phosphate dehydrogenase subunit A Proteins 0.000 description 1
- 101710113668 Anaerobic glycerol-3-phosphate dehydrogenase subunit C Proteins 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12392598 | 1998-04-02 | ||
| IL12392598 | 1998-04-02 | ||
| PCT/IL1999/000190 WO1999051725A2 (en) | 1998-04-02 | 1999-03-30 | Assay for the diagnosis of schizophrenia based on a new peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69928236D1 DE69928236D1 (de) | 2005-12-15 |
| DE69928236T2 true DE69928236T2 (de) | 2006-08-03 |
Family
ID=11071395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69928236T Expired - Lifetime DE69928236T2 (de) | 1998-04-02 | 1999-03-30 | Peptid für die diagnose von schizophrenie |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7098304B1 (enExample) |
| EP (1) | EP1068303B1 (enExample) |
| JP (1) | JP4364433B2 (enExample) |
| CN (1) | CN1171995C (enExample) |
| AR (1) | AR014811A1 (enExample) |
| AT (1) | ATE309335T1 (enExample) |
| AU (1) | AU3165599A (enExample) |
| BR (1) | BR9909308B1 (enExample) |
| CA (1) | CA2324380C (enExample) |
| DE (1) | DE69928236T2 (enExample) |
| IL (1) | IL138746A (enExample) |
| TW (1) | TW581812B (enExample) |
| WO (1) | WO1999051725A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002037105A1 (en) * | 2000-10-31 | 2002-05-10 | Japan As Represented By President Of Niigata University | Diagnostic kit for schizophrenia |
| JP5048205B2 (ja) | 2001-03-21 | 2012-10-17 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 精神分裂病の診断のための新規ペプチド |
| CN1300588C (zh) * | 2005-02-28 | 2007-02-14 | 上海交通大学 | 用于精神分裂症诊断的血浆特异性蛋白获取方法及应用 |
| WO2007091881A2 (en) * | 2005-04-29 | 2007-08-16 | Leiden University Medical Center | Methods and means for detection of mycobacterium leprae infections |
| JP2018524595A (ja) * | 2015-07-14 | 2018-08-30 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | 統合失調症の診断で使用するためのペプチドの組み合わせ |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026107A1 (en) * | 1993-05-13 | 1994-11-24 | New York University | Psychosis protecting nucleic acid, peptides, compositions and method of use |
| US6008001A (en) * | 1993-11-05 | 1999-12-28 | Yeda Research And Development Co. Ltd. | Diagnosis of the susceptibility of contracting schizophrenia |
| CA2184602A1 (en) * | 1994-03-01 | 1995-09-08 | Meir Shinitzky | Assay for the diagnosis of schizophrenia |
-
1999
- 1999-03-30 DE DE69928236T patent/DE69928236T2/de not_active Expired - Lifetime
- 1999-03-30 AT AT99913557T patent/ATE309335T1/de not_active IP Right Cessation
- 1999-03-30 US US09/647,457 patent/US7098304B1/en not_active Expired - Lifetime
- 1999-03-30 EP EP99913557A patent/EP1068303B1/en not_active Expired - Lifetime
- 1999-03-30 WO PCT/IL1999/000190 patent/WO1999051725A2/en not_active Ceased
- 1999-03-30 AU AU31655/99A patent/AU3165599A/en not_active Abandoned
- 1999-03-30 BR BRPI9909308-1A patent/BR9909308B1/pt not_active IP Right Cessation
- 1999-03-30 CN CNB998059951A patent/CN1171995C/zh not_active Expired - Fee Related
- 1999-03-30 CA CA002324380A patent/CA2324380C/en not_active Expired - Fee Related
- 1999-03-30 JP JP2000542438A patent/JP4364433B2/ja not_active Expired - Lifetime
- 1999-03-31 TW TW088105128A patent/TW581812B/zh not_active IP Right Cessation
- 1999-03-31 AR ARP990101492A patent/AR014811A1/es not_active Application Discontinuation
-
2000
- 2000-09-28 IL IL138746A patent/IL138746A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL138746A (en) | 2006-12-10 |
| ATE309335T1 (de) | 2005-11-15 |
| JP2002510712A (ja) | 2002-04-09 |
| CN1300320A (zh) | 2001-06-20 |
| WO1999051725A2 (en) | 1999-10-14 |
| WO1999051725A3 (en) | 1999-12-02 |
| EP1068303A2 (en) | 2001-01-17 |
| AR014811A1 (es) | 2001-03-28 |
| JP4364433B2 (ja) | 2009-11-18 |
| US7098304B1 (en) | 2006-08-29 |
| BR9909308A (pt) | 2001-10-02 |
| AU3165599A (en) | 1999-10-25 |
| HK1030966A1 (en) | 2001-05-25 |
| CA2324380A1 (en) | 1999-10-14 |
| CA2324380C (en) | 2009-02-24 |
| CN1171995C (zh) | 2004-10-20 |
| TW581812B (en) | 2004-04-01 |
| EP1068303B1 (en) | 2005-11-09 |
| DE69928236D1 (de) | 2005-12-15 |
| BR9909308B1 (pt) | 2010-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69420556T2 (de) | Assay für troponin i aus dem herzmuskel | |
| Mikol et al. | A phosphatidylinositol-linked peanut agglutinin-binding glycoprotein in central nervous system myelin and on oligodendrocytes. | |
| DE69113273T2 (de) | Zellnekrosnachweis durch prüfung von spektrin und seine abbauprodukte. | |
| DE10303974A1 (de) | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung | |
| Timerman et al. | Inositol polyphosphate receptor and clathrin assembly protein AP-2 are related proteins that form potassium-selective ion channels in planar lipid bilayers. | |
| DE69133393T2 (de) | Verfahren zur diagnose und behandlung von diabetes | |
| Schwob et al. | Purification and characterization of an antigen that is spatially segregated in the primary olfactory projection | |
| DE60017019T2 (de) | Antikörper gegen Spaltprodukte von Vimentin | |
| DE69030494T2 (de) | Karzinomverwandtes haptoglobin (hpr) | |
| DE69928236T2 (de) | Peptid für die diagnose von schizophrenie | |
| DE69733957T2 (de) | Verfahren zur bestimmung der gegenwart des gehirnspezifischen proteins s-100 beta | |
| DE69606651T2 (de) | Test zur diagnose von demenz | |
| DE69629976T2 (de) | Typ I Prokollagen aminoterminales Propeptid, dessen Antikörper und Testverfahren unter Verwendung davon | |
| EP0815141B1 (de) | Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid | |
| DE102007025291A1 (de) | Verfahren und Immunabsorbentien zur spezifischen Detektion und Absorption Zöliakie- und Dermatitis herpetiformis assoziierter Antikörper | |
| DE69331585T2 (de) | Monoklonaler antikörper spezifisch für das fk-506-bindende protein, methode zur bestimmung des gehaltes an fk-506-bindendem protein in einer probe und reagenzsatz dafür | |
| Greenberger et al. | Membrane glycoproteins of the nerve growth cone: diversity and growth regulation of oligosaccharides. | |
| DE4130786A1 (de) | Peptide zur herstellung von mitteln zur diagnose und therapie von systemischen lupus | |
| Cortas et al. | Anomalous mobilities of Na, K-ATPase α subunit isoforms in SDS-PAGE: identification by N-terminal sequencing | |
| EP0137345B1 (de) | Membranassoziierte Proteine (MP2), Verfahren zu ihrer Gewinnung sowie ihre Verwendung | |
| DE69012572T2 (de) | Monoklonaler antikörper gegen acetylierte lysinabfälle in rekombinantem rindsomatotropin. | |
| JPS62500304A (ja) | 膵臓がんに伴う胞状奇胎分化蛋白質、これらの蛋白質に対する抗血清およびモノクロ−ナル抗体、製造方法 | |
| DE69400936T2 (de) | Peptid entsprechend einem Epitop des menschlichen Parvovirus B19 | |
| US5429929A (en) | Method for detecting antibodies to a neuroblastoma antigen in mental illness | |
| DE3785614T2 (de) | Antigenisches peptid der 28kd proteingruppe aus s. mansoni und sein verfahren zur isolierung, monoklonale antikoerper, die mindestens ein epitop dieses peptids erkennen und verwendungen fuer die induzierung der synthese von neutralisierenden antikoerpern. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: YEDA RESEARCH & DEVELOPMENT CO., LTD., WEIZMANN IN |
|
| 8364 | No opposition during term of opposition |